Related Experiment Video
Updated: Jul 17, 2025
An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
A plain language summary on preventing fungal infections with isavuconazole in people with blood-related conditions
Yang Ping1, Jing Hongmei1, Christian Bellmann2
1Peking University Third Hospital, Beijing, People's Republic of China.
What Is This Summary About?:
People with blood-related conditions have a higher chance of getting invasive fungal infections (IFIs). IFIs are severe fungal infections that can lead to death. Only a few medications, known as antifungals, exist that can be used to prevent IFIs, and sometimes they can cause very bad side effects. Isavuconazole is an antifungal which has been approved to treat IFIs, but it has not been approved to prevent IFIs. In this study, we reviewed published studies that looked at how well isavuconazole prevented IFIs in people who have a higher chance of getting IFIs.
What Were The Results?:
This review showed that isavuconazole could be effective at preventing IFIs in people with blood-related conditions, as well as being a safe medication.
What Do The Results Of The Study Mean?:
Isavuconazole can prevent IFIs in people who have a higher chance of getting IFIs. Guidelines should consider that patients need new antifungals to prevent IFIs, and more research needs to be done to see which medicines work best, and which have fewer side effects. Clinical Trial Registration: Please note that 7 studies included in this review were planned studies (1 prospective, 6 retrospective), 2 were real- world studies, 1 of which was registered as a clinical trial NCT03019939 (ClinicalTrials.gov).
Insights
Isavuconazole shows promise in preventing invasive fungal infections (IFIs) for individuals with blood disorders. This antifungal medication appears effective and safe, offering a potential new option for high-risk patients.
Area of Science:
- Mycology
- Hematology
- Infectious Diseases
Background:
- Invasive fungal infections (IFIs) pose a significant mortality risk, particularly in patients with hematologic conditions.
- Limited antifungal options for IFI prophylaxis often present severe adverse effects.
- Isavuconazole, an approved antifungal for IFI treatment, lacks established prophylactic use.
Purpose of the Study:
- To review existing literature on the efficacy and safety of isavuconazole for IFI prophylaxis.
- To evaluate isavuconazole's potential role in preventing IFIs in immunocompromised populations.
Main Methods:
- Systematic review of published studies investigating isavuconazole's prophylactic use.
- Inclusion of planned (prospective and retrospective) and real-world studies.
- Analysis of data from studies involving patients at increased risk for IFIs.
Main Results:
- Isavuconazole demonstrated potential efficacy in preventing IFIs among individuals with blood-related conditions.
- The medication was found to be generally safe for prophylactic use in this patient group.
- Review included studies of varying designs, with one registered clinical trial (NCT03019939).
Conclusions:
- Isavuconazole may serve as an effective and safe prophylactic agent against IFIs in at-risk populations.
- Clinical guidelines should consider novel antifungal agents for IFI prevention.
- Further research is warranted to compare the effectiveness and safety profiles of different prophylactic antifungals.
More Related Videos
Related Concept Videos
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:28Fungal Phylum Microsporidia
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...